Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Glenmark Pharmaceuticals Limited and Glenmark Generics Inc US have signed a settlement and licensing pact with Triax Pharmaceuticals, Astellas Pharma Europe and Astellas Pharma International to settle its lawsuit related to generic version of Locoid Lipocream.
Subscribe to our email newsletter
The lawsuit was filed in connection with Glenmark‘s submission of an abbreviated new drug application (ANDA) for 0.1% hydrocortisone butyrate cream, Glenmark’s generic version of Locoid Lipocream.
As per the terms of the licensing and settlement agreement, Glenmark will get permission for marketing and distributing 0.1% hydrocortisone butyrate cream under a royalty-bearing license from Astellas and Triax in the US near the end of 2013.
With this settlement, Glenmark believes that it is eligible for 180 days of exclusivity with respect to its hydrocortisone butyrate cream, as the first generic company to file an ANDA for the product.